These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11904987)

  • 1. [Development of antiangiogenic chemotherapy regimens].
    Takahashi H; Kondo T
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):237-43. PubMed ID: 11904987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic scheduling of lower dose cancer chemotherapy.
    Gately S; Kerbel R
    Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
    Taillade L; Alexandre I; Billemont B; Meric JB; Sultan-Amar V; Rixe O
    Bull Cancer; 2009; 96 Suppl 1():S45-55. PubMed ID: 19433373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of angiogenesis in cancer patients.
    Verheul HM; Pinedo HM
    Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapies in breast cancer.
    Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.
    Samuel DP; Wen PY; Kieran MW
    Expert Opin Investig Drugs; 2009 Jul; 18(7):973-83. PubMed ID: 19548852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
    Gasparini G; Longo R; Fanelli M; Teicher BA
    J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibitors. New anticancer strategy.
    Zgodziński W; Wallner G; Dabrowski A
    Pol J Pharmacol; 1999; 51(6):455-62. PubMed ID: 10817522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.